UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
current report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date
of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
(Address of principal executive offices) (Zip Code)
(
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether either registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if either registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 5.07 | Submission of Matters to a Vote of Security Holders. |
The annual meeting of stockholders (the “Annual Meeting”) of Select Medical Holdings Corporation (the “Company”) was held on April 28, 2022. At the Annual Meeting, the Company’s stockholders approved three proposals. The proposals below are described in the Company’s definitive proxy statement dated March 4, 2022. The results are as follows:
Proposal 1: The Election of Four Class I Directors to the Board of Directors
| Name | Votes For | Votes Against | Abstentions | Broker Non-Votes | ||||||||||
| Russell L. Carson | 113,073,166 | 11,939,484 | 35,514 | 2,792,649 | ||||||||||
| Katherine R. Davisson | 124,036,792 | 977,167 | 34,205 | 2,79???649 | ||||||||||
| William H. Frist | 116,539,779 | 8,473,222 | 35,163 | 2,792,649 | ||||||||||
| Marilyn B. Tavenner | 116,779,415 | 8,235,066 | 33,683 | 2,792,649 | ||||||||||
Proposal 2: Non-Binding Advisory Vote on the Compensation of the Company’s Named Executive Officers
| Votes For | Votes Against | Abstentions | Broker Non-Votes | ||||||||
| 108,422,682 | 16,580,508 | 44,974 | 2,792,649 | ||||||||
Proposal 3: Ratification of the Appointment of PricewaterhouseCoopers LLP as the Company’s Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2022
| Votes For | Votes Against | Abstentions | Broker Non-Votes | ||||||||
| 126,801,925 | 1,001,953 | 36,935 | 0 | ||||||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrants have duly caused this report to be signed on their behalf by the undersigned, thereunto duly authorized.
| SELECT MEDICAL HOLDINGS CORPORATION |
| Date: April 29, 2022 | By: | /s/ Michael E. Tarvin |
| Michael E. Tarvin | |
| Executive Vice President, General Counsel and Secretary |